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John F. Greden 
Introduction 
The positive/negative symptom dichotomy is 
being increasingly utilized to explain the bet- 
erogeneity of schizophrenia, and poor response 
to neuroleptic treatment has traditiona!ly been 
considered to be one of the characteristic fea- 
tures of the negative syndrome. This issue was 
emphasized by Crow (1980), who principally 
based this conclusion on the study by Iohnstone 
et al. (1978), which found that cis-flupenthixol, 
a dopamine (DA) receptor blocker, significantly 
reduced positive symptoms, but was no more 
effective on negative symptoms than trans-flu- 
penthixol, an isomer of cis-flupenthixol without 
DA antagonist properties. Crow suggested that 
increased dopaminergic activity was the basis 
of the neuroleptic-responsive positive symptoms 
which were predominant in the so-called type I 
syndrome, whereas structural brain abnormali- 
ties marked by ventricular enlargement were the 
basis of the neuroleptic-nonresponsive negative 
symptoms that characterized the type II syn- 
drome. The association between negative symp- 
toms, poor response to neurolepfics, and yen- 
From the Schizophrenia Program, University of Michigan Medical 
Center, Ann Arbor, MI. 
Presented at the Forty-fourth annual meeting of the Society of Bi- 
olosical Psychiatry, San Francisco, May 4--8, 1989. 
Address reprint requests to Rajiv Tandon, M.D., Director, Schizo- 
phrenia Program, Box 0120, University of Michigan Medical 
Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109. 
Received September 16, 1989; revised December 8, 1989. 
tricular enlargement was confirmed in several 
later studies (Andreasen et al. 1982; Angrist et 
al. 1980; Pearlson et al. 1984; Weinberger et 
al. 1980). 
The National Institute of Mental Health and 
Veteran's Administration collaborative studies 
completed 25 years ago (Cole et al. 1966), how- 
ever, had noted significant improvement in in- 
dividual negative symptoms in schizophrenic 
patients as a consequence of neuroleptic treat- 
ment. This finding of improvement in negative 
symptoms has been confirmed in several recent 
studies (Breier et al. 1987; vanKammen et al. 
1987; Kay and Singh 1989). One of these stud- 
ies noted that improvement in negative symp- 
toms was significantly correlated to the im- 
provement in positive symptoms (vanKammen 
1987), but another observed no such relation- 
ship (Breier et al. 1987). 
In an effort to study the question of whether 
negative symptoms change with neuroleptic 
treatment and to evaluate the covariance of pos- 
itive and negative symptoms, we assessed pos- 
itive and negative symptoms in 40 schizophrenic 
inpatients at drug-free baseline and 4 weeks after 
neuroleptic treatment. 
Materials and Methods 
The sample consisted of 40 consecutively hos- 
pitalized patients who were admitted to the In- 
patient Schizophrenia Program at the University 
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of Michigan. Diagnostic evaluation included a 
structured interview using the Schedule of Af- 
fective Disorders and Schizophrenia (SADS) 
(Endicott and Spitzer 1978) as well as all avail- 
able history and clinical observations. Patients 
had to meet both DSM-III-R (American Psy- 
chiatric Association 1987) and Research Diag- 
nostic Criteria (RDC) (Spitzcr et al. 1978) cri- 
teria for schizophrenia and give informed consent 
for participation in the study. The sample con- 
sisted of 27 men and 13 women with a 
mean __ SD age of 30 ----- 6 years and a mean 
duration of illness of 6 -_- 4 years. Twelve of 
the patients had never previously received any 
psychotropic medication, and 28 had previously 
received neuroleptics. 
Baseline clinical ratings were performed after 
patients were medication free for at least 2 weeks. 
Patients were then placed on clinically deter- 
mined doses of haloperidol or thiothixene singly, 
or in combination with 2-6 mg of trihexypheni- 
dyl if they developed extrapyramidal side-ef- 
fects. After about 4 weeks of neuroleptic treat- 
ment, clinical ratings were repeated. Patients were 
rated on the Brief Psychiatric Rating Scale (BPRS) 
(Overall and Gotham 1962), and the Scale for the 
Assessment of Negative Symptoms (SANS) 
(Andreasen 1983) at both timepoints. Assess- 
ment of global severity was made by the 18-item 
BPRS total score. Positive symptoms were as- 
sessed by the sum of the following seven BPRS 
items: conceptual disorganization, mannerisms 
and posturing, hostility, suspiciousness, halluci- 
natory behavior, unusual thought content, and 
excitement. Negative symptoms were assessed by 
the SANS, with the sum of global scores being 
used for analysis. 
Paired two-tailed t-tests were performed to 
compare the symptom ratings at baseline to those 
in the posttreatment phase. Correlation analysis 
between change ~ positive %anptoms and change 
in negative symptoms was conducted to evaluate 
the covariance of these symptom clusters. 
Results 
Both positive and negative symptoms were found 
to improve significantly (p < 0.001) with neu- 
roleptic treatment (Table 1). Although positive 
symptoms improved to a greater extent than neg. 
ative symptoms (Figure 1), this difference was 
not statistically significant. Drug-naive and pre- 
viously treated patients showed the same pattern 
of improvement (Figure 1). Use of the BPRS 
"THOT" factor (consisting of conceptual dis- 
organization, suspiciousness, hallucinatory be- 
havior, and unusual thought content) to define 
positive symptoms or the BPRS "AblER" factor 
(consisting of emotional withdrawal, motor re- 
tardation, and blunted affect) to define negative 
symptoms did not alter the findings. 
Change in positive symptoms was signifi- 
cantly correlated to change in negative symp- 
toms (r = 0.63, p < 0.001). Even ff a nar- 
rower definition of p3sitive symptoms (the BPRS 
"THOT" factor) was employed, change in pos- 
itive symptoms continued to be significantly 
correlated to change in negative symptoms 
(r = 0.60, p < 0.001). 
Discussion 
The observed improvement in negative symp- 
toms with neuroleptic treatment is consistent with 
the findings of other recent studies (Breier et al. 
1987; vanKammen et al. 1987; Kay and Singh 
1989) that have documented such improvement. 
Similar to the findings of these studies, we ob- 
served that positive symptoms improved to a 
somewhat greater extent than negative symp- 
toms. The significant correlation between c~ange 
in posiuve and negative symptoms noted in this 
study is in agreement with the findings of 
vanKammen et al. (1987), but inconsistent with 
Breier et al, (1987), who did not find such a 
relationship. The failure of Breier et al. to find 
this relationship may have been related to their 
relatively smaller sample size (n = 19). 
The covariance of positive and negative 
symptoms with reference to neuroleptic treat- 
ment indicates that common or related patho- 
physiological mechanisms may underly positive 
and negative symptoms in the psychotic phase 
of the illness. In an effort to reconcile discrepant 
findings with regard to neuroleptic responsive- 
ness of negative symptoms, Meltzer (1985, in 
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Table 1. Positive and Negative Symptom Ratings at Baseline and Following 4 Weeks of 
Neuroleptic Treatment 
Symptom measures Baseline Posttreatment t 
Sig.n_if icCnce 
df P 
Global severity (BPRS total) 
Positive symptoms (BPRS subscale) 
Negative symptoms 
(SANS sum of global scores) 
49.3 + 8.0 35.0 _+ 7.3 11.0 
21.6 - 4.9 13.4 - 4.0 9.8 
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Figure 1. Degree of symptom improvement from baseline to posttreatment. 
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press) suggested that the effect of treatment on 
negative symptoms is dependent on positive 
symptom improvement; our findings are con- 
sistent with this contention. Alternatively, the 
concurrent improvement in positive and nega- 
tive symptoms observed in our study is also 
consistent with the recently proposed model of 
dopaminergic/cholinergic interactions in schizo- 
phrenia (Tandon and Greden 1989) which sug- 
gests that distinct but related pathophysiological 
mechanisms underly positive (dopaminergic hy- 
peractivity) and negative (muscarinic choliner- 
gic hyperactivity) symptoms in this phase of the 
illness. 
Though the validity of these inferences can 
be determined only through further study, these 
data are inconsistent with the characterization 
of negative symptoms as always being neuro- 
leptic nonresponsive and suggest that common 
or related mechanisms may underly positive and 
negative symptoms in the psychotic phase of the 
illness. 
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